Clinical Report: Metastasis to the Heart in Sarcomatoid Urothelial Carcinoma
Overview
This report details a rare case of cardiac metastasis from sarcomatoid urothelial carcinoma (SUC) in a 55-year-old woman. Following treatment with tislelizumab monotherapy, the patient exhibited significant regression of the right ventricular mass, suggesting a potential therapeutic avenue for similar cases.
Background
Sarcomatoid urothelial carcinoma (SUC) is a rare and aggressive form of urothelial carcinoma, comprising less than 2% of all cases. Its propensity for distant metastasis, particularly to uncommon sites such as the heart, poses significant clinical challenges. Understanding the management of such cases is crucial due to the limited treatment options and poor prognosis associated with SUC.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
Cardiac metastasis from urothelial carcinoma is exceedingly rare, with few documented cases.
The patient presented with right renal pelvis SUC and developed a large right ventricular mass during treatment.
Tislelizumab monotherapy resulted in significant regression of the cardiac mass.
The case highlights the aggressive nature of SUC and the potential for immune checkpoint inhibitors in treatment.
High PD-L1 expression in SUC may indicate responsiveness to PD-1 inhibitors.
Clinical Implications
This case underscores the importance of considering cardiac metastasis in patients with advanced SUC. Immune checkpoint inhibitors like tislelizumab may offer a viable treatment option for patients intolerant to traditional chemotherapy regimens.
Conclusion
This case represents the first documented instance of isolated right ventricular metastasis from SUC responding to anti-PD-1 therapy, suggesting a need for further exploration of immunotherapy in similar patient populations.
